SPC69
Crizotinib, mögulega á formi lyfjafræðilega hæfs salts, hýdrats eða lausnarsambands þar af
Status:
VeittApplication date:
19.3.2013Application published:
15.4.2013Grant published:
15.9.2013
Max expiry date:
25.10.2027Next due date:
31.8.2026Medicine name:
XalkoriMedicine for children:
Yes
Timeline
Today
19.3.2013Application
15.4.2013Publication
15.9.2013Registration
14.8.2026Expires
Marketing license
IS authorization number:
EU/1/12/793/001-004Date:
8.11.2012
Foreign authorization number:
EU/1/12/793/001-004Date:
23.10.2012
Owner
Name:
Pfizer Inc.Address:
66 Hudson Boulevard East, New York, NY 10001-2192 US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113 Reykjavík
Patent
Number:
EP1786785
Annual fees
Number
Paid
Expires
Payer
Number: 1
Paid: 7.7.2025
Expires: 14.8.2026
Payer: Árnason Faktor ehf.
Deadlines
TypeDeadline until
Type: Frestur til að fara yfir drög að vottorði
Deadline until: 17.12.2025